反应详情

Following the procedure for 1-((1H-imidazol-2-yl)methyl)-6-(4-(1-aminocyclobutyl)phenyl)-7-phenyl-1H-pyrido[2,3-b][1,4]oxazin-2(3H)-one, tert-butyl(1-(4-(2-methyl-1-oxo-8-phenyl-2,4-dihydro-1H-pyrido[2,3-b][1,2,4]triazolo[4,3-d][1,4]oxazin-7-yl)phenyl)cyclobutyl)carbamate (26 mg, 0.05 mmol) was reacted to afford the title compound (18 mg, 56%). LCMS (method D): RT=0.764 min, M-NH2=409. 1H NMR (500 MHz, MeOD): 8.56 (1H, s), 7.45 (2H, d), 7.41 (2H, d), 7.33-7.31 (3H, m), 7.24-7.23 (2H, m), 5.43 (2H, s), 3.53 (3H, s), 2.78-2.72 (2H, m), 2.59-2.53 (2H, m), 2.25-2.18 (1H, m), 1.99-1.91 (1H, m).

1. customwas reacted